Medindia

X

Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma

Wednesday, December 2, 2009 General News J E 4
Advertisement

KERYX CONTACT:

Lauren Fischer

Director, Investor Relations

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5962

E-mail: lfischer@keryx.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
PDL BioPharma Announces December 15 Special Divide...
S
Spartan Introduces 'NEAT' New Vehicle for the Non ...